Diabetes is the
fastest growing disease in history with some 387M or more cases globally
estimated this year by the International Diabetes Federation (IDF), a figure
that is set to rise roughly 53% over the next two decades. The most disturbing
statistic is the 175M or more of those cases that go undiagnosed. The IDF data
paints an alarmingly clear picture, diabetes is on the rise in every country on
earth; in fact, one out of every 12 humans has diabetes and one out of every
two people with diabetes doesn’t even know they have it. The IDF estimates that
as many as 628M people globally are pre-diabetic or have Type 2 diabetes
(adult-onset or non–insulin-dependent diabetes), with projections through 2030
indicating a 45% jump to around 912M.
Here in the U.S. we
are spending more on healthcare to combat diabetes than anywhere else on the
planet, with $612B (or 11% of all healthcare spending on adults) spent in 2014
alone, and the American Diabetes Association’s (ADA) data indicates that not
only is diabetes the number seven killer in the country, it was also a leading
underreported cause of death. Some 40% of people who died of diabetes did not
have it listed anywhere on the death certificate according to ADA’s research,
and the Centers for Disease Control and Prevention (CDC) estimates that if this
trend continues as many as one out of every three Americans will have diabetes
by 2050. Troubling statistics indeed when one considers the nearly 5M
fatalities this year in the U.S. from diabetes, or one death every seven
seconds.
Last year, over 79k
children developed Type 1 diabetes (roughly 10% of all cases, formerly known as
juvenile-onset or insulin-dependent diabetes) and over 21M births were affected
by diabetes during pregnancy as well. Moreover, despite the incident rate being
highest among persons aged 40 to 59 years, some 208k Americans under the age of
20 are estimated to have been diagnosed this year according to the ADA. This
clearly documents that Type 2 diabetes, once virtually unheard of in people under
30, is now rapidly on the rise, with childhood obesity playing a major role.
Type 1 diabetes can
be averted if caught early and diabetics can even turn the disease around
completely with proper diet and exercise, but the high number of undiagnosed
cases is a serious red flag here, pointing directly to the costs, complexities
and invasiveness of testing. Early detection and intervention is absolutely key
to preventing Type 1 diabetes, and with average medical expenditures as much as
2.3 times higher for diabetics than those without it, public health
organizations and governments are now starting to get serious about creating
initiatives designed to tackle the problem.
Many people go
untested due to the invasiveness or daunting logistics of existing testing
methods, involving blood draws, fasting, trips to the doctor and/or lab, and
waiting for test results to come back. The common A1C test for instance
(sometimes also called the HbA1c test), which measures an individual’s average
blood sugar level over the past few months, requires a sizeable blood sample
and is the most common route for testing. The FPG test (fasting plasma glucose)
or the OGTT test (oral glucose tolerance, commonly done to check for diabetes
that occurs with pregnancy, or gestational diabetes), while less expensive and
generally very easy to do compared to the A1C, are similarly problematic, given
that patients must fast for 8 to 14 hours prior to taking the test and must
still give a blood sample(s).
People’s reluctance
to get tested and the subsequent healthcare costs associated with increased
morbidity, may have finally met their match though in the form of the novel,
non-invasive Scout DS® system from Miraculins, Inc. (TSX-V: MOM) (OTCM: MCUIF).
This first-of-its-kind device is a sleek looking, small form factor tabletop
system, featuring an LCD display and an arm rest that the patient places their
forearm onto for the test. After only about 80 seconds the device painlessly
produces a highly accurate score on a scale from 0 to 100 using a series of LED
lights and sensors. The device uses a well-established testing methodology
called skin fluorescence spectroscopy (SFS) to measure advanced glycation end
products (AGEs), which have been vetted through numerous studies over the past
25 years as a highly sensitive metric for gauging the cumulative impact of
abnormally high blood sugar and oxidative stress on the body.
Until recently, AGE
measurement required a punch biopsy of the skin big enough to require a stitch
and a costly/complex assay for which only a handful of academic laboratories
had the capability, making this approach to screening for diabetes essentially
non-commercially viable. The Scout DS however uses quantitative SFS
(multivariate spectroscopy using a unique algorithm) to measure collagen
cross-links and other fluorescent AGEs, via a set of unique UV/Blue LEDs to
stimulate fluorescence, as well as some White LEDs to compensate for skin tone
variations. With more than 3k subjects to date tested in prospective clinical
trials, the accuracy and efficacy of the Scout DS for doing rapid, non-invasive
screening of pre-diabetes and Type 2 diabetes, by measuring diabetes related
biomarkers in the skin, now looks to be firmly established.
The efficacy of
this rapid testing technology was even recently demonstrated in a peer-reviewed
study (ENGINE) of the Scout DS published in the Journal of Clinical and
Translational Endocrinology. The study showed the device’s ability to detect
abnormal glucose tolerance just as well as (if not better than) FPG or A1C
testing, all without fasting or blood draws, adding further credence to the
commercial viability of the Scout DS as a rapid non-invasive screening system
for diabetes, as well as the accuracy and robustness of the innovative SFS/AGE
testing methodology which lies at the heart of the device’s design. The Scout
DS is 61% more sensitive than A1C and 100% more sensitive than FPG (ENGINE
study), with a 93% detection rate for Type 2 diabetes (TCOYD1 study), and is
1.4 times better than RCG with an equivalent false-positive rate (random
capillary glucose, Greece study), yet the device easily works on people with
dark skin (LSS study versus OGTT).
In China, which has
overtaken India as the world leader in diabetes cases, with upwards of 92M
diabetics (again, nearly half of whom are undiagnosed), there is a massive
target market for such a device as the Scout DS. Miraculins hasn’t wasted any
time acquiring inroads to this target-rich environment and executed a
definitive agreement in August to sell and distribute up to $90M worth of Scout
DS devices via Hong Kong-based Catalyn Medical Technologies, Ltd., with Cachet
Pharmaceutical Co., Ltd. already tapped as exclusive distributor for mainland
China.
Also in August,
Miraculins detailed their fast-track strategy for obtaining de novo FDA
classification (intended for “novel” devices with a low risk profile) on the
Scout DS, with a pre-submission designed to follow up on last year’s filing for
feedback from the FDA regarding a clinical/regulatory roadmap for marketing
clearance, in light of the reasonable assurance of safety and effectiveness of
the device, as well as the absence of any existing or comparable device on the
market. Obtaining de novo status from the FDA would put the Scout DS on the
road to a Class I or Class II medical device classification (cheaper and easier
than a Class III designation) and confidence is high at Miraculins that the FDA
will be cooperative, especially when the planned data to be gathered and
submitted is supplied.
For more
information, visit www.miraculins.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. We offer several ways for investors
to find, evaluate, and learn more about investing in these companies.
Sign up for “The
QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks
Daily Blog http://blog.qualitystocks.net
The Quality Stocks
Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks
“Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment